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Abstract
Importance
Chronic fatigue syndrome (CFS) is characterised by a constellation of symptoms diagnosed
with a number of different polythetic criteria. Heterogeneity across these diagnostic criteria
is likely to be confounding research into the as-yet-unknown pathophysiology underlying
this stigmatised and debilitating condition and may diagnose a disease spectrum with signifi-
cant implications for clinical management. No studies to date have objectively investigated
this possibility using a validated measure of CFS symptoms–the DePaul Symptom Ques-
tionnaire (DSQ).
Objective
To examine whether current CFS diagnostic criteria are identifying different disease pheno-
types using the DSQ.
Design
Case control study.
Setting
Clinical Research Facility of the Royal Victoria Infirmary, Newcastle upon Tyne, UK.
Participants
49 CFS subjects and ten matched, sedentary community controls, excluded for co-morbid
depression.
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Main outcomes and measures
Self-reported autonomic and cognitive features were assessed with the Composite Auto-
nomic Symptom Score (COMPASS) and Cognitive Failures Questionnaire (COGFAIL)
respectively. Objective autonomic cardiovascular parameters were examined using the
Task Force®Monitor and a battery of neuropsychological tests administered for objective
cognitive assessment.
Results
Self-reported autonomic and cognitive symptoms were significantly greater in CFS subjects
compared to controls. There were no statistically significant differences in objective auto-
nomic measures between CFS and controls. There were clinically significant differences
between DSQ subgroups on objective autonomic testing. Visuospatial memory, verbal
memory and psychomotor speed were significantly different between DSQ subgroups.
Conclusions and relevance
The finding of no significant differences in objective autonomic testing between CFS and
control subjects may reflect the inclusion of sedentary controls or exclusion for co-morbid
depression. Consistent exclusion criteria would enable better delineation of these two condi-
tions and their presenting symptoms. Findings across CFS subgroups suggest subjects
have a different disease burden on subjective and objective measures of function, auto-
nomic parameters and cognitive impairment when categorised using the DSQ. Different
CFS criteria may at best be diagnosing a spectrum of disease severities and at worst differ-
ent CFS phenotypes or even different diseases. This complicates research and disease
management and may contribute to the significant stigma associated with the condition.
Introduction
Chronic fatigue syndrome (CFS) is a disabling and stigmatising illness of unknown aetiology.
Its current UK prevalence is estimated to be at least 0.2–0.4%[1]; studies using broader screen-
ing procedures have yielded prevalence estimates of over 2%[2]. CFS is a diagnosis of exclusion
based on a number of different sets of polythetic diagnostic criteria developed empirically over
the last three decades to reflect the many presenting symptoms. The diagnostic and prognostic
salience of the different signs and symptoms is unknown and this inclusion of multiple symp-
toms involving many body systems complicates clinical diagnosis and is likely to add to the
stigma associated with the condition.
It is widely recognised that there are limitations to these diagnostic sets and that there is dis-
parity between them[3–7]. The different sets may identify different categorical groups differing
in phenotypic pattern and which can be conceptualised as subtypes of CFS or even different
disorders or may relate to a continuum across which different thresholds are arbitrarily met
dependent on diagnostic schedule used[8, 9].
The DePaul Symptom Questionnaire (DSQ) was devised by Leonard Jason et al as a devel-
opment of the CFS Questionnaire[10] to better, and more consistently, assess the “core” symp-
toms of CFS. Frequency and severity of symptoms, demographics, and medical, occupational,
and social history are self-reported over a retrospective six-month period using a 5-point
CFS phenotypes
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Likert scale to give a “diagnosis” of CFS based on the Fukuda criteria[11], the 2003 Canadian
clinical[12] or research[13] criteria and the 2011 Canadian consensus criteria [14] (Table 1). It
has been shown to have good inter-rater and test-retest reliability and validity in the differenti-
ation of individuals with CFS, major depressive disorder (MDD), and healthy controls[15–17].
Autonomic dysfunction in CFS has consistently been reported in studies[19], as has a
potential sequela cognitive dysfunction [20]. However, the nature of these finding lacks unifor-
mity, which may be related to heterogeneity within CFS patients or to systematic differences in
sample selection between studies based on differing inclusion criteria, diagnostic rigour or
Table 1. Chronic fatigue syndrome diagnostic criteria.
Criteria Major Minor
Fukuda criteria/ CDC 1994
criteria [11]
• six months of severe chronic fatigue not due to exertion or
other illness and interfering with daily life
 four of the following eight symptoms:
• Post-exertional malaise of >24 hours
• Unrefreshing sleep
• Impairment to short-term memory or concentration
• Myalgia
• Arthralgia without swelling/erythema
• Headaches of new type
• Lymphadenopathy
• Frequent or recurring sore throat
Canadian consensus 2003
[12]
(DSQ 2003 clinical
guidelines)
 six months of:
• Significant new-onset, unexplained, persistent fatigue that
reduces activity level, and/or
• Post-exertional malaise, and/or
• Sleep dysfunction and/or
• Pain in the form of widespread myalgia/arthralgia or
headaches
 two neurological/cognitive symptoms:
• Confusion
• Poor concentration and short-term memory
• Poor information processing, categorising and word
retrieval
• Perceptual and sensory disturbances
• Ataxia
• Muscle weakness
• Fasciculations
and one from two of the following categories:
• Autonomic: orthostatic intolerance, PoTS, nausea,
irritable bowel, urinary frequency, palpitations, exertional
dyspnoea
• Neuroendocrine: loss of thermostatic stability, weight
change
• Immune: lymphadenopathy, recurrent sore throat,
general malaise, sensitivities to food/medications
DSQ revised Canadian
research criteria [18]
• New, persistent or recurring fatigue for at least six months
which impacts usual activities
• Post-exertional malaise and/or post-exertional fatigue
• Unrefreshing or disturbed sleep
• Widespread or migratory pain
• two neurological or cognitive symptoms
• one autonomic/neuroendocrine/immune manifestation
Absence of any active medical condition that may explain
the presence of chronic fatigue
Canadian (International)
consensus 2011 [14]
• Postexertional neuroimmune exhaustion with marked,
prolonged post-exertional physical or cognitive fatigue with
extended recovery period
 one symptom from three of these categories:
• Neurocognitive impairment
• Pain
• Sleep disturbance
• Neurosensory, perceptual and motor disturbances
 one symptom from three of these categories:
• Flu-like symptoms
• Susceptibility to viral infections
• Gastro-intestinal tract symptoms
• Genitourinary symptoms
• Sensitivities
 one symptom from these categories:
• Cardiovascular
• Respiratory
• Loss of thermostatic stability
• Intolerance of extremes of temperature
https://doi.org/10.1371/journal.pone.0186885.t001
CFS phenotypes
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recruitment strategy. Here we report subjective and objective measures of disease severity,
autonomic dysfunction and cognitive impairment in CFS subjects and matched comparators,
as well as the impact of DSQ categorisation between subgroups, to elicit whether different
diagnostic criteria identify a spectrum of disease phenotypes.
Materials and methods
Recruitment
Participants were recruited as part of a Medical Research Council funded study Understanding
the pathogenesis of autonomic dysfunction in chronic fatigue syndrome and its relationship
with cognitive impairment. Recruitment was conducted between November 2012 and April
2014. CFS subjects were recruited from the Newcastle upon Tyne and regional specialist CFS
services. All met Fukuda criteria as diagnosed by physician via clinical interview and con-
firmed with administration of the DSQ during study screening. Matched sedentary controls
were recruited via university volunteer databases, advertisements and word of mouth. Partici-
pants with co-morbid hypertension or psychiatric disorder diagnosed using the Structured
Clinical Interview for DSM-IV Research Version were excluded. Cardioactive medications
were withheld for 72 hours prior to assessment. Patients and controls were matched for age,
gender, employment or education status and premorbid IQ (using the validated National
Adult Reading Test.
The MRC study was conducted in accordance with the recommendations for physicians
involved in research on human subjects adopted by the 18th World Medical Assembly, Hel-
sinki 1964 and later revisions. Informed consent was obtained.
Favourable ethical opinion was obtained from the NRES Committee North East—Newcas-
tle & North Tyneside 2 prior to commencement of the study. Local research and development
approval was obtained from Newcastle upon Tyne Hospitals NHS Foundation Trust’s
Research and Development office. All participants provided written, informed consent.
DePaul symptom questionnaire
The DSQ is a self-reported 99-item questionnaire measuring CFS symptoms, demographic
information and medical, social and occupational history according to the Canadian Clinical
Criteria, the ME International Consensus Criteria, and the Fukuda criteria[16, 21]. It is avail-
able in the shared library of Research Electronic Data Capture (REDCap), hosted at DePaul
University: https://redcap.is.depaul.edu/surveys/?s=tRxytSPVVw. After scoring for symptom
frequency and severity, patients are categorised into one of four criteria groups: the Fukuda;
the Fukuda+2003 Canadian Clinical; the Fukuda+2003 Canadian Research, or the Fukuda
+2003+2011 Canadian (Table 1). Those meeting the Fukuda+2003 Clinical differ from the
Fukuda+2003 Research in that they do not meet the more stringent Research criteria requiring
the presence of major symptoms.
Other questionnaires
The Fatigue Impact Scale (FIS) assesses the impact that subjective fatigue has on daily func-
tioning[22]. Forty items are scored on a 5-point Likert scale providing a continuous scale of
0–160. A higher score indicates greater impact.
Participants completed the Autonomic Symptom Profile[23] as a self-report measure of
autonomic symptoms. However, scoring was performed according to the recently abbreviated
and psychometrically improved version of this questionnaire, the Composite Autonomic
Symptom Score 31 (COMPASS 31)[24]. Scoring consists of 31 items from six domains–
CFS phenotypes
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orthostatic intolerance, vasomotor, secretomotor, gastrointestinal, bladder, pupillomotor–
each weighted according to number of items and clinical relevance. Weighted individual
domain scores are totalled to a maximum of 100, indicating greater symptom load.
The Cognitive Failures Questionnaire (COGFAIL)[25] comprises 25 questions measuring
the frequency of self-reported failures in perception, memory and motor function in the previ-
ous six months and is answered on a 5-point Likert scale giving a possible total score of 100.
Higher scores indicate greater impairment.
There is currently no standardised way to measure self-reported activity levels. The short
version of the International Physical Activity Questionnaire (IPAQ) gives a measure of physi-
cal activity over the preceding seven days[26] and has been shown to be a reliable measure of
self-reported physical activity[27]. The questionnaire asks about three types of activity: walk-
ing, moderate-intensity activities and vigorous-intensity activities, undertaken during leisure
time, domestic and gardening activities, work-related physical activity and transport-related
physical activity. The duration (minutes) and frequency (days) of activity is scored to give
METs, multiples of resting metabolic rate, equated to levels of activity and described as low,
moderate or high.
Participant characteristics
Demographic information, symptom burden, function and diagnostic information were
obtained by participant report and questionnaire, as above.
Autonomic assessment
Autonomic assessment was conducted at the Clinical Research Facility at the Royal Victoria
Infirmary. The Task Force1 Monitor (TFM, CNSystems Medizintechnik, Graz, Austria) was
used to record and analyse continuous heart rate (HR) (electrocardiogram (ECG)) and beat-
to-beat blood pressure (BP) assessment. It is a reliable and reproducible method of non-inva-
sive autonomic assessment[28, 29].
Participants were instructed to eat a light breakfast, avoid caffeine and alcohol on the day of
testing and refrain from nicotine for two hours before assessment. All assessments were per-
formed between 9–10am. TFM recordings were taken during a ten-minute supine rest, a two-
minute active stand and a Valsalva manoeuvre.
Cognitive assessment
The battery of neuropsychological tests focussed on memory and concentration, shown to be
features of cognitive impairment in CFS[30], and assessed verbal and non-verbal memory,
recall, recognition and learning skills. Tests reported here are the Rey Auditory-verbal learning
test (AVLT) to assess verbal learning and memory, the Digit Symbol Substitution Test (DSST)
to assess psychomotor speed, Digit Span for working and short-term memory, Spatial Span for
working and short-term dynamic visuospatial memory and the Visual Patterns Test (VPT) to
assess short-term fixed visuospatial memory. Tests were conducted under time pressure and
commenced immediately after autonomic assessment. Caffeine, alcohol and nicotine were
avoided as above.
Statistical analysis
Data were analysed using GraphPad Prism version 6. The difference between CFS patients and
control participants in normally-distributed continuous data was analysed using the unpaired
t-test, at a 5% and 1% significance level, as indicated. Unpaired continuous skewed data were
CFS phenotypes
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analysed using the non-parametric Mann Whitney U test. The differences between the four
patient sub-groups according to DSQ criteria was analysed using ANOVA or the Kruskal-Wal-
lis test for non-parametric datasets. A 5% significance level is given. For significant ANOVA
findings Bonferroni-corrected post-hoc test results are reported. (In addition, as increasingly
stricter criteria are applied to the four DSQ diagnostic groups, the assigned sub-group mem-
bership can be considered an ordinal variable. Accordingly, Kendall’s tau-b tests were per-
formed to assess the strength of the monotonic relationship between diagnostic category and
the various measures.)
Results
Study cohort
Seventy-six potential participants were invited for screening, of whom sixty-nine were eligible.
Eight withdrew from the study; one was lost to follow-up and one commenced a new medica-
tion resulting in loss of eligibility. In total, 59 participants (CFS n = 49; controls n = 10) under-
went autonomic and cognitive testing.
Participant characteristics
Patients and controls were well-matched with no significant differences between age, gender,
employment or education status, or pre-morbid IQ (Table 2). Age range was of CFS partici-
pants was 23–68 years. Age range of controls was 25–65 years. Co-morbidities were self-
Table 2. Baseline characteristics.
Controls Fukuda Fukuda Fukuda + Fukuda
(n = 10) alone + 2003 2003 + 2003
(n = 6) Clinical Research + 2011
(n = 9) (n = 8) (n = 26)
Age (years)
mean (SD) 49 (15.3) 43 (14.5) 50 (14.0) 41 (10.9) 47 (11.1)
range 26–68 23–61
Male n (%) 3 (30%) 1 (17%) 5 (56%) 1 (13%) 6 (30%)
Employed n (%) Yes 3 (30%) 3 (50%) 4 (44%) 3 (38%) 7 (27%)
Full time 1 (10%) 0 (0%) 4 (44%) 0 (0%) 3 (12%)
Part time 2 (20%) 3 (50%) 0 (0%) 3 (38%) 4 (15%)
Paid 3 (30%) 3 (50%) 4 (44%) 3 (38%) 7 (27%)
Voluntary 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Student n (%) 2 (20%) 0 (0%) 0(0%) 0(0%) 0(%)
Years in Education n (%) 11 1 (10%) 1 (17%) 1 (11%) 0 (0%) 8 (31%)
>11 9 (90%) 5 (83%) 8 (89%) 8 (100%) 18 (69%)
Highest qualification
n (%)
None 0 (0%) 0 (0%) 0 (0%) 1 (13%) 2 (8%)
GCSE 2 (20%) 1 (17%) 1 (11%) 0 (0%) 11 (42%)
A level 2 (20%) 0 (0%) 1 (11%) 3 (38%) 6 (23%)
Degree 6 (60%) 5 (83%) 7 (78%) 4 (50%) 7 (27%)
Premorbid IQ mean (SD) 122 (4.3) 119 (6.6) 117 (6.6) 123 (3.1) 116 (9.2)
Co- morbidities n (%) 7 (70%) 5 (83%) 8 (89%) 7 (88%) 25 (96%)
Cardioactive medication n (%) 0 (0%) 1 (17%) 5 (56%) 2 (25%) 10 (38%)
https://doi.org/10.1371/journal.pone.0186885.t002
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reported by affected system and include cardiorespiratory, neurological, gastrointestinal and
endocrine disease. The presence of co-morbidities was higher in the CFS group compared to
controls (92% versus 70%). Among CFS participants, those meeting the Fukuda+2003
Research and Fukuda+2003+2011 criteria had lower educational attainment and were less
likely to be in employment.
Symptom burden
CFS participants self-reported statistically significantly greater fatigue, cognitive impairment
and autonomic symptoms (Table 3). IPAQ scores in both groups were lower than those seen
in active, healthy volunteers in other studies, who have shown median scores of 4500–6000[31,
32], and reflect the sedentary lifestyle of participants in this study. Nevertheless, controls had
significantly higher IPAQ scores than CFS subjects (1230 (IQR 821) v. 203 (1002)) which may
represent the cumulative effect of nonstrenuous activity not achievable by CFS patients
because of illness burden.
Across DSQ subgroups there are statistically significant differences in FIS and COMPASS
31 scores, and there was a statistical trend for a monotonic increase of self-reported cognitive
impairment with increased DSQ category. Participants meeting the Fukuda+2003+2011 crite-
ria had the highest subjective levels of fatigue, cognitive impairment and symptoms of dysauto-
nomia compared to the other CFS diagnostic subgroups. The lowest scores are seen in the
group meeting Fukuda alone.
Table 3. IPAQ scoring and outcome measures by DSQ.
Controls all CFS Fuk- Fukuda Fukuda Fukuda + p value p
uda + 2003 + 2003 2003 + (ANOVA/ value
alone Clinical Re- 2011 Mann (Kend-
search Whitney) all tau-
(n = 10/ (n = 49/ (n = 6) (n = 9/ (n = 8/ (n = 26/ b)
9#) 46#) 8#) 7#) 25#)
FIS n/a 91.7 58.2$ 81.7 93.1 102.5$ 0.013* 0.004
(32.5) (34.1) (19.3) (22.4) (33.3) **
COGFAIL 32.3 53.9 42.0 49.6 54.1 58.2 0.250 0.094
(10.0) (19.1)** (17.4) (15.8) (20.9) (19.3)
COM- 8.1 38.6 26.3$ 31.3 37.2 44.4$ 0.015* 0.002
PASS 31 (5.7) (15.2)** (13.5) (12.8) (6.7) (15.8) **
IPAQ
score
median 1230 203 819 908 208 33 0.041*
(IQR) (821) (1002)* (1418) (983) (1040) (565)
Low (n) 2 29 2 4 4 19
(22%) (63%) (33%) (50%) (57%) (76%)
Mod- 6 16 4 4 3 5
erate (n) (67%) (35%) (67%) (50%) (43%) (19%)
High (n) 1 (11%) 1 (2%) 0 (0%) 0 (0%) 0 (0%) 1 (4%)
# Questionnaire data were incomplete for one or more participants in each of these groups
* significant at 5% level
** significant at 1% level
$ significant Bonferroni-corrected post-hoc tests between these groups
Values expressed as mean (SD)
https://doi.org/10.1371/journal.pone.0186885.t003
CFS phenotypes
PLOS ONE | https://doi.org/10.1371/journal.pone.0186885 October 20, 2017 7 / 16
Autonomic nervous system at rest
Objective testing did not reveal any statistically significant differences between CFS and con-
trol subjects (Table 4). Resting heart rate (HR) and blood pressure (BP) were at the lower end
of the normal clinical reference range in both groups. Examination of HR and BP variability
appeared to show a shift to increased sympathetic modulation in both groups compared to
normal reference ranges. Baroreflex control was within normal limits in CFS and control
subjects.
There were no statistically significant differences in HR and BP between DSQ subgroups.
Fukuda alone subjects had the lowest HR and Fukuda+2003+2011 the highest. Although not
statistically significant, mean measures in the Fukuda+2003+2011 group are overall lower for
all parameters except TPRI. Measures in the Fukuda alone group are higher compared to other
subgroups, also with the exception of TPRI.
Autonomic nervous system in response to standing and Valsalva
Neither mean BP nor nadir on standing was statistically or clinically significantly different and
30:15 ratio–an indicator of parasympathetic activity–was within normal parameters.
The CFS group has a statistically significantly longer Valsalva ratio compared to the control
group; however, both groups had an abnormal ratio (<1.21) indicating dysautonomia. Low
baseline blood pressure may help to explain these results.
Valsalva ratio was abnormal in all DSQ subgroups indicating dysautonomia. There are sta-
tistically significant between-group differences in Phases I and Iii, which may reflect parasym-
pathetic activation by the baroreceptors[33].
Cognitive performance
Results are detailed by domain tested and shown in Table 5.
Memory: Verbal
There was a statistically significant inter-group difference in total recall over trials 1–5 on
AVLT. Participants in the Fukuda+2003+2011 group underperformed (score 43.7) compared
to the other groups–an indication of a less efficient verbal declarative memory–with those
meeting a Fukuda+2003 Research ‘diagnosis’ performing best (53.0). The difference between
these groups resulted in the only significant post-hoc test. Furthermore, the Fukuda+2003
+2011 group also had the lowest percentage retention on trial A7 (70.5%) and the Fukuda
+2003 Research group the highest (84.2%), but this was not statistically significant.
Memory: Visuospatial
There are statistically significant differences across all measures on spatial span and VPT at
least at trend level. Participants in the Fukuda+2003+2011 group had the lowest scores in for-
ward spatial span and VPT compared to the other subgroups. For forward spatial span the dif-
ference to the Fukuda only group reached statistical significance in post hoc tests. For VPT the
difference to the two Fukuda+2003 groups was significant. This suggests this group has a defi-
cit in immediate spatial memory compared to the others[34, 35]. Although the Fukuda+2003
+2011 group also has the lowest score in backward spatial span among the patient subgroups
and there is a difference between the subgroups in this measure at statistical trend level
(p = 0.066), this seems to be driven more by higher scores in the Fukuda+2003 Research group
(M = 5.9) than by the poor performance in the Fukuda+2003+2011 group, but none of the
post-hoc tests reached statistical significance.
CFS phenotypes
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Table 4. Autonomic function (heart rate and blood pressure variability and beat statistics, active stand and Valsalva) by DSQ.
Control all CFS Fukuda Fukuda
+ 2003
Fukuda
+ 2003
Fukuda
+ 2003
p value p value
Clinical Research + 2011 (ANOVA/ (Kendall
Pearson tau-b)
(n = 10/9#) (n = 49/
47#)
(n = 6) (n = 9) (n = 8) (n = 26/24#) χ2)
Beat statistics HR (bpm) 76.62
(7.11)
75.02
(9.84)
70.26
(5.46)
73.07 (9.24) 75.92 (6.36) 76.52
(11.48)
0.501 0.227
sBP (mmHg) 104.87
(11.19)
108.09
(19.62)
102.94
(20.80)
122.27
(24.99)
100.07
(12.72)
106.83
(17.51)
0.083 0.664
dBP (mmHg) 67.86
(6.55)
68.81
(11.77)
69.10
(20.49)
71.90
(14.75)
63.82 (6.10) 69.20 (9.50) 0.567 0.821
mBP (mmHg) 78.23
(7.63)
79.03
(13.06)
78.44
(20.71)
83.65
(15.55)
73.75 (7.06) 79.20
(11.57)
0.497 0.806
Heart rate variability LFnu-RRI 62.42
(12.89)
58.80
(17.08)
55.63
(13.22)
68.60
(13.42)
64.74
(19.54)
54.31
(17.06)
0.111 0.108
HFnu-RRI 37.58
(12.89)
41.20
(17.08)
44.37
(13.22)
31.40
(13.42)
35.27
(19.54)
45.69
(17.06)
0.111 0.108
LF/HF-RRI 2.25 (1.16) 2.44 (2.68) 2.23 (1.94) 3.14 (1.87) 4.08 (5.37) 1.75 (1.50) 0.144 0.064
Diastolic BP variability LFnu-dBP 46.81
(19.01)
53.63
(13.54)
54.49
(13.88)
55.66
(10.97)
62.63
(10.41)
49.96
(14.24)
0.126 0.199
HFnu-dBP 12.48
(10.75)
14.10
(10.82)
11.89
(5.66)
14.59 (8.75) 9.93 (7.52) 15.73
(12.98)
0.575 0.895
LF/HF-dBP 6.13 (4.20) 6.94 (5.44) 5.76 (2.69) 5.91 (3.87) 11.09 (8.28) 6.29 (4.97) 0.129 0.763
Systolic BP variability LFnu-sBP 38.48
(13.86)
46.41
(14.08)
46.10
(16.33)
46.85
(11.71)
56.91
(11.52)
43.10
(14.12)
0.114 0.299
HFnu-sBP 15.43
(10.68)
17.58
(11.83)
14.89
(5.54)
16.77
(10.22)
9.44 (8.33) 20.98
(13.21)
0.094 0.220
LF/HF-sBP 3.80 (2.43) 4.68 (4.41) 3.48 (1.43) 4.14 (2.80) 10.58
(7.30)$ $
3.33 (2.48) < .001** 0.193
Baroreflex sensitivity ms/mmHg 11.66
(9.58)
13.63
(8.83)
20.68
(16.40)$
13.17 (9.35) 19.10 (7.50) 10.47
(4.49)$
0.012* 0.070
Baroreflex
effectiveness index
58.08
(15.49)
60.77
(18.71)
64.63
(32.27)
56.26
(16.39)
73.53
(18.61)
57.51
(18.69)
0.150 0.401
Active Stand nadir sBP 89.70
(16.66)
98.88
(26.60)
101.33
(17.63)
111.78
(29.45)
85.75
(28.50)
97.88
(25.96)
0.249 0.450
drop sBP 19.80
(9.19)
11.44
(12.20)*
7.00 (6.50) 13.57
(17.13)
13.79 (8.00) 11.01
(12.54)
0.719 0.806
drop > 20mmHg 5 (50%) 9 (18%)* 0 (0%) 2 (22%) 1 (12%) 6 (23%) 0.571 -
30:15 ratio 1.14 (0.18) 1.20 (0.31) 1.37 (0.67) 1.28 (0.36) 1.15 (0.20) 1.15 (0.17) 0.355 0.521
AUC baseline 259.3
(294.3)
109.9
(256.4)
29.95
(45.73)
274.8
(503.8)
82.26
(98.97)
79.72
(171.3)
0.191 0.977
Valsalva minimum RR 478.9
(126.0)
522.4
(120.6)
469.8
(94.7)
585.0
(128.5)
488.9 (99.9) 523.2
(125.3)
0.246 0.591
RR rebound 981.2
(213.1)
788.1
(210.3)*
880.5
(244.7)
749.9
(180.9)
748.8
(210.4)
792.5
(217.2)
0.640 0.705
Peak I sBP 140.00
(17.33)
137.70
(23.76)
143.33
(13.84)
139.00
(24.11)
132.13
(30.45)
137.67
(24.15)
0.857 0.683
Trough IIe sBP 101.78
(15.63)
108.62
(21.16)
108.50
(20.47)
114.67
(21.07)
102.38
(24.99)
108.46
(20.79)
0.711 0.705
Peak III sBP 126.89
(12.66)
134.79
(24.06)
134.17
(20.46)
143.78
(24.60)
122.38
(30.02)
135.71
(22.27)
0.339 0.834
Trough III sBP 118.44
(15.43)
126.38
(25.87)
123.50
(19.55)
135.00
(26.15)
112.75
(28.97)
128.42
(25.72)
0.336 0.811
(Continued)
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These findings suggest that visuospatial working memory, which allows temporary reten-
tion and manipulation of information[36] (spatial span) and short-term visuospatial memory
(VPT)[37], differs by diagnostic criteria and may be impaired in participants meeting Fukuda
Table 4. (Continued)
Control all CFS Fukuda Fukuda
+ 2003
Fukuda
+ 2003
Fukuda
+ 2003
p value p value
Clinical Research + 2011 (ANOVA/ (Kendall
Pearson tau-b)
(n = 10/9#) (n = 49/
47#)
(n = 6) (n = 9) (n = 8) (n = 26/24#) χ2)
Peak IV sBP 148.33
(30.76)
143.47
(27.39)
152.00
(19.72)
147.89
(28.64)
136.50
(26.05)
142.00
(29.65)
0.718 0.511
AUC (baseline) 233.2
(371.3)
115.2
(137.4)
107.9
(70.1)
134.22
(134.0)
68.0 (90.1) 125.6
(164.2)
0.749 0.638
Time below (1st to
last)
15.83
(19.54)
11.60
(12.25)
12.28
(6.24)
12.07
(10.38)
7.28 (5.98) 12.70
(15.34)
0.760 0.441
Time below
(baseline)
15.18
(19.73)
9.68
(11.16)
8.24 (5.26) 11.22
(10.07)
6.14 (6.16) 10.65
(13.76)
0.752 0.818
Values expressed as mean (SD) or n (%)
* significant at 5% level
** significant at 1% level
$ $ significant post-hoc differences from all other subgroups
$ significant post-hoc differences between indicated groups
# two patients and one control participant were unable to complete Valsalva manoeuvre
https://doi.org/10.1371/journal.pone.0186885.t004
Table 5. Cognitive testing by DSQ.
all CFS Fukuda Fukuda Fukuda + Fukuda + p value p value
+ 2003 2003 2003 + (ANOVA) (Kendall
Clinical Research 2011 tau-b)
(n = 49/48)# (n = 6) (n = 9) (n = 8) (n = 26/25#)
Rey AVLT
Total recall trials 1–5 47.2 (8.8) 51.3 (6.3) 49.4 (11.7) 53.0 (4.47)$ 43.7 (7.8)$ 0.017* 0.001**
Forgetting (% retained from A6 on trial A7) 75.7 (21.2) 80.1(23.2) 80.3 (12.0) 84.2 (14.8) 70.5 (24.2) 0.322 0.112
Forward Digit Span
Clinical measure 6.6 (1.4) 6.7 (1.2) 6.9 (1.5) 6.4 (1.2) 6.6 (1.5) 0.906 0.772
Spatial span
Forward longest sequence 5.1 (1.3) 6.3 (0.8)$ 5.4 (1.5) 5.6 (0.9) 4.5 (1.1)$ 0.002** <0.001**
Backward longest sequence 4.9 (1.2) 5.0 (0.9) 4.8 (1.6) 5.9 (0.6) 4.6 (1.2) 0.066 0.184
VPT
Maximum number of targets 9.9 (2.3) 10.5 (1.2) 11.0 (2.0)@ 11.4 (1.9)@ 8.8 (2.2)@@ 0.005** 0.003**
DSST
Symbols per second 0.58 (0.16)* 0.7 (0.1)$ 0.6 (0.1) 0.7 (0.1) 0.5 (0.2)$ 0.016* 0.011*
Values are expressed as mean (SD)
* significant at 5% level
** significant at 1% level$ significant post-hoc differences between groups
@ significant post-hoc differences of these groups and @@ group
# One participant was unable to complete Spatial Span and VPT
https://doi.org/10.1371/journal.pone.0186885.t005
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+2003+2011 criteria. There was an effect of group on the number of symbols recorded per sec-
ond on the DSST, with the fewest symbols completed in the Fukuda+2003+2011 group, which
was statistically different from the Fukuda only group in post-hoc tests.
Discussion
CFS subjects reported significantly greater autonomic and cognitive impairment compared to
matched, sedentary controls; however, findings did not show significant objective autonomic
differences. There were significant differences in subjective cognitive and autonomic measures
on DSQ categorisation, as well as clinical differences in objective assessment of autonomic and
cognitive function. Possible interpretation of these results is discussed below.
CFS versus controls
The lack of statistically significant objective difference in autonomic function in this cohort
of CFS and control subjects differs from previous studies that have demonstrated a differ-
ence in autonomic function[19, 38] and may reflect a number of factors. Firstly, sedentary
controls were selected for participation. Previously demonstrated autonomic dysfunction in
CFS subjects compared to controls may have arisen secondary to inactivity and consequent
deconditioning.
Secondly, this study excluded participants with a history of co-morbid depression. Auto-
nomic dysfunction has been found in depression[39]. It is possible that autonomic dysfunction
seen in other studies results from co-morbid depression and is not a primary feature of CFS.
Consistent exclusion criteria across studies and research centres would enable better delinea-
tion of these two conditions and their presenting symptoms.
Finally, it is feasible that autonomic dysfunction experienced by CFS subjects, manifesting
as HR and BP abnormalities, is intermittent. Although assessment using the TFM provides a
continuous measure it is conducted over approximately 20 minutes implying that intermittent
symptoms may not be captured.
DSQ
Autonomic function measured using HR and BP variability assessed over a 10-minute rest
suggests differences in the balance between sympathetic and parasympathetic autonomic func-
tion with Fukuda+2003 Research showing greater sympathetic activity and Fukuda+2003
+2011 lower sympathetic modulation of cardiovascular activity.
LF/HF-sBP is highest in the Fukuda+2003 Research group suggesting a shift towards
greater sympathetic activity in this group. It is lowest in the Fukuda+2003+2011 group and
suggests lower sympathetic activity, further supported by a low LFnu-sBP indicative of low
sympathetic modulation of sBP, and of a higher HFnu-sBP, suggesting greater parasympa-
thetic modulation.
Although not statistically significant, this points towards the presence of different pheno-
types across DSQ subgroups, suggesting that AD may differ by diagnostic criteria when con-
sidered at a clinical level.
The differences observed between DSQ subgroups may be a reflection of the additive effect
in diagnostic criteria. The absence of autonomic symptoms in the Fukuda criteria implies a
different, less severe, disease phenotype with fewer features of AD. In contrast, symptoms of
AD are present in the 2003 criteria and include ataxia, muscle weakness and OI. Further still,
the 2011 criteria have a requirement for a greater symptom burden, which can include wide-
spread migratory pain and hyperalgesia.
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The possibility that current criteria include symptoms that are not primary features of CFS,
specifically in relation to the Canadian 2011 criteria which encompasses a broad spectrum of
symptoms across body systems, and confounds clinical presentation and research, must be
considered. The number of symptoms across many physiological symptoms included in the
Canadian 2011 criteria may mean that, rather than diagnosing a more severe CFS phenotype,
these criteria capture both CFS and other co-morbidities with non-specific symptoms. This
may not only affect management and subsequent prognosis, but also give rise to an inaccurate
and confused picture of which condition (or conditions) is being researched and serve to exac-
erbate the stigma associated with the condition.
Furthermore, it is possible that the inclusion of more widespread pain with or without
hyperalgesia in the 2011 criteria may be a confounding symptom–particularly in view of the
association between pain and both autonomic dysfunction and cognitive impairment (atten-
tion, psychomotor speed, verbal and working memory)[40–42].
There was only a statistical trend for a monotonic relationship between DSQ subgroups
and self-reported cognitive impairment with COGFAIL. Fukuda+2003+2011 subjects reported
higher scores than all other subgroups, pointing towards greater impairment in this group.
Comparison of objective measures between DSQ diagnostic subgroups revealed statistically
significant between-group differences in verbal memory–as assessed using the AVLT total
score, visuospatial memory and psychomotor speed, with the Fukuda+2003+2011 subgroup
consistently showing greater impairment, in particular than the Fukuda alone group. These
findings mirror subjectively higher scores of cognitive impairment on COGFAIL, greater
fatigue on FIS and more autonomic symptoms on COMPASS. Fukuda alone and Fukuda
+2003 Clinical appeared to perform better.
Given the findings of the ANOVAs and the patterns of post-hoc results, there appears to
be an additive effect in the DSQ criteria where more symptoms result in greater symptom
burden and disease severity and points towards a subgroup of patients with greater func-
tional impairment. The results of the monotonic trend tests (Kendall tau-b) often support
this notion. These findings contribute to a picture of potentially clinically significant and
distinct phenotypic differences between DSQ subgroups and the possibility of CFS as a dis-
ease spectrum.
One of the study strengths was that it recruited a highly-motivated cohort of CFS subjects
who completed a comprehensive series of investigations enabling, for the first time, in-
depth observation of the potential phenotypic differences between DSQ subgroups. There
are a number of limitations to acknowledge including the small number of controls and
small sample sizes in DSQ subgroups, which means the study is underpowered. In particular
the comparisons between the full patient sample and the small control sample are likely to
suffer from problems with variance inhomogeneity. Conducting clinical research in this
group of patients presents challenges in recruiting adequate numbers and this study would
have benefitted from additional control subjects to increase statistical validity. The study
results point towards the possibility of a spectrum of disease phenotypes as shown across
diagnostic criteria. These phenotypes appear to be quantitative in nature, i.e. of symptom/
disease severity, however a small study population of CFS subjects well enough to attend
several appointments and therefore likely to represent milder disease severity, mean this is
difficult to characterise. Future studies would benefit from exploring the possibility that
clusters of participants represent different disease phenotypes to better explore whether
they represent discrete, qualitative traits. This study is observational and therefore disease
causality cannot be determined.
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Conclusions
Findings of no significant differences in objective autonomic parameters between CFS and
control groups raises questions about the role of co-morbid depression and sedentary controls
and strongly indicates that more consistent inclusion and exclusion criteria across studies is
key to furthering understanding of CFS pathophysiology.
This is the first study investigating objective differences in autonomic and cognitive features
across DSQ subgroups. It suggests that CFS–as classified using current diagnostic criteria–may
constitute a disease spectrum, with different severities. This has potentially significant reper-
cussions for further understanding of the underlying aetiopathogenesis of this debilitating
condition, contributing to the sometimes conflicting and mixed results seen across studies,
and implications for response to clinical management.
This study suggests that there are differences in objective autonomic parameters across
groups of CFS subjects. Damage to the autonomic nervous system appears to take the form of
an initial sympathetic over-modulation followed, in more severe disease, by sympathetic
underactivity and increased parasympathetic modulation, as seen with subjects meeting the
Fukuda+2003 Research and Fukuda+2003+2011 criteria respectively. This supports the theory
that abnormalities in the autonomic nervous system are a potentially important feature of CFS
and hold promise for better understanding the underlying pathophysiology of this condition.
This study highlights the need for international consensus with regard to diagnosis. The
recent development of the Institute of Medicine criteria will go some way to achieving this but
it is vital that there is consistency in diagnostic approach when performing research in this
condition where novel therapies are so urgently needed.
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